Damora Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Damora Therapeutics, Inc. carries a market capitalization of 1.83B, placing it among publicly traded companies globally. Its enterprise value stands at -81.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.83B |
| Enterprise Value | -81.46M |
Share Statistics
Damora Therapeutics, Inc. currently has 60.30M shares outstanding.
| Shares Outstanding | 60.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.62 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | -12.82 |
| P/OCF Ratio | -12.82 |
Financial Position
Damora Therapeutics, Inc. maintains a current ratio of 22.48, meaning it holds 22.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 22.48 |
| Quick Ratio | 22.42 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -85.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 90,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Damora Therapeutics, Inc.'s stock has gained approximately 816.92308% over the past 52 weeks. The 50-day moving average sits at 23.89, while the 200-day moving average is 21.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 816.92308% |
| 50-Day Moving Average | 23.89 |
| 200-Day Moving Average | 21.39 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -238.99M, while operating income came in at -239.08M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -239.08M |
| Pretax Income | -235.00M |
| Net Income | -235.09M |
| EBITDA | -238.99M |
| EBIT | -239.08M |
| Earnings Per Share (EPS) | -19.09 |
Balance Sheet
Total book value stands at -515.14M, with working capital of 511.60M providing operational flexibility.
| Cash & Cash Equivalents | 532.90M |
| Total Debt | N/A |
| Net Debt | -532.90M |
| Equity (Book Value) | -515.14M |
| Book Value Per Share | -41.83 |
| Working Capital | 511.60M |
Cash Flow
Damora Therapeutics, Inc. produced -24.88M in operating cash flow over the past twelve months.
| Operating Cash Flow | -24.88M |
| Capital Expenditures | N/A |
| Free Cash Flow | -24.88M |
| FCF Per Share | -2.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -92.77 |
| FCF Yield | -7.80 |
Scores
Damora Therapeutics, Inc. posts an Altman Z-Score of 6.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.35 |